RNAC
NASDAQCartesian Therapeutics Inc.
News · 26 weeks48-56%
2025-12-142026-06-07
Mix1890d
- SEC Filings8(44%)
- Other7(39%)
- Insider3(17%)
Latest news
25 items- SECCartesian Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Cartesian Therapeutics, Inc. (0001453687) (Filer)
- PRCartesian Therapeutics Announces Strategic Licensing Agreement with WestGene Biopharma to Accelerate the Development of In Vivo CAR-T Platform in Autoimmune DiseasesWestGene's established targeted LNP platform combined with Cartesian's mRNA payload from Descartes-08 integrates two independently, clinically tested technologies for rapid clinical translation Plans to advance multiple Cartesian-owned, internally developed next-generation anti-BCMA CAR constructs and a BCMA-directed TCE as part of expanding mRNA payload portfolio Clinical trial expected to initiate in 2H 2026 using mRNA payload from Descartes-08 combined with WestGene's LNP platform in patients with MG; Clinical data expected in 1H 2027 FREDERICK, Md., June 09, 2026 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ:RNAC) (the "Company" or "Cartesian"), a late clinical-stage biot
- SECCartesian Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities, Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Cartesian Therapeutics, Inc. (0001453687) (Filer)
- PRCartesian Therapeutics Secures up to $150 Million of Non-Dilutive Financing from K2 HealthVentures and Expects Topline Data from the Phase 3 AURORA Trial in First Quarter 2027Secured up to $150 million of non-dilutive financing from K2 HealthVentures; funding of $50 million from initial tranche extends cash runway into 2028 Financing strengthens Cartesian's financial flexibility, further supporting advancement of multiple clinical programs to data read out including myasthenia gravis and myositis, while also accelerating pre-launch activities Topline data from Phase 3 AURORA trial of Descartes-08 in myasthenia gravis expected in 1Q27; BLA filing planned for mid-2027 Data from subset of patients in Phase 2 TRITON trial of Descartes-08 in myositis expected in 1H27 Data from Phase 1/2 HELIOS pediatric trial of Descartes-08 in juvenile dermatomyositis expected in
- PRCartesian Therapeutics to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQFREDERICK, Md., May 12, 2026 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ:RNAC) (the "Company"), a late clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced that its management expects to participate in a fireside chat at the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ on Tuesday, May 19, 2026, at 3:00 p.m. ET. A live webcast of the presentation and fireside chat is expected to be accessible in the Events section of the Company's website at www.cartesiantherapeutics.com, where an archived replay of the events will also be available for a limited time. About Cartesian Therapeutics Cartesian Therapeutics
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Cartesian Therapeutics Inc.SCHEDULE 13G/A - Cartesian Therapeutics, Inc. (0001453687) (Subject)
- PRCartesian Therapeutics Announces New Employment Inducement GrantsFREDERICK, Md., May 04, 2026 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ:RNAC) (the "Company"), a late clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced the granting of inducement awards to five new employees. On May 1, 2026, the Company issued to these employees options to purchase an aggregate of 317,200 shares of the Company's common stock with an exercise price of $6.22, the closing trading price of the Company's common stock on the Nasdaq Global Market on the date of grant. The options were granted pursuant to the Company's Amended and Restated 2018 Employment Inducement Incentive Award Plan and were approved by the Comp
- SECSEC Form S-8 filed by Cartesian Therapeutics Inc.S-8 - Cartesian Therapeutics, Inc. (0001453687) (Filer)
- SECSEC Form 10-Q filed by Cartesian Therapeutics Inc.10-Q - Cartesian Therapeutics, Inc. (0001453687) (Filer)
- SECCartesian Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Cartesian Therapeutics, Inc. (0001453687) (Filer)
- PRCartesian Therapeutics Reports First Quarter 2026 Financial Results and Provides Business UpdateEnrollment continues to progress in Phase 3 AURORA trial of Descartes-08 in myasthenia gravis Phase 2 TRITON trial of Descartes-08 in dermatomyositis and antisynthetase syndrome initiated Multiple patients enrolled in Phase 1/2 HELIOS pediatric trial of Descartes-08 in juvenile dermatomyositis Approximately $120.4 million cash, cash equivalents and restricted cash as of March 31, 2026, expected to support planned operations into mid-2027, including completion of ongoing Phase 3 AURORA trial FREDERICK, Md., April 30, 2026 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ:RNAC) ("we", the "Company" or "Cartesian"), a late clinical-stage biotechnology company pioneering cell thera
- SECSEC Form DEF 14A filed by Cartesian Therapeutics Inc.DEF 14A - Cartesian Therapeutics, Inc. (0001453687) (Filer)
- SECSEC Form DEFA14A filed by Cartesian Therapeutics Inc.DEFA14A - Cartesian Therapeutics, Inc. (0001453687) (Filer)
- INSIDERSEC Form 4 filed by Hoge Elizabeth4 - Cartesian Therapeutics, Inc. (0001453687) (Issuer)
- INSIDERSEC Form 4 filed by Kalayoglu Murat4 - Cartesian Therapeutics, Inc. (0001453687) (Issuer)
- PRCartesian Therapeutics Announces New Employment Inducement GrantsFREDERICK, Md., April 02, 2026 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ:RNAC) (the "Company"), a late clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced the granting of inducement awards to two new employees. On April 1, 2026, the Company issued to these employees options to purchase an aggregate of 52,450 shares of the Company's common stock with an exercise price of $6.39, the closing trading price of the Company's common stock on the Nasdaq Global Market on the date of grant. The options were granted pursuant to the Company's Amended and Restated 2018 Employment Inducement Incentive Award Plan and were approved by the Co
- SECCartesian Therapeutics Inc. filed SEC Form 8-K: Leadership Update8-K - Cartesian Therapeutics, Inc. (0001453687) (Filer)
- INSIDERDirector Singer Michael gifted 6,555 units of Common Stock, decreasing direct ownership by 12% to 49,578 units (SEC Form 4)4 - Cartesian Therapeutics, Inc. (0001453687) (Issuer)
- ANALYSTCartesian Therapeutics upgraded by Cantor Fitzgerald with a new price targetCantor Fitzgerald upgraded Cartesian Therapeutics from Neutral to Overweight and set a new price target of $16.00
- SECSEC Form 10-K filed by Cartesian Therapeutics Inc.10-K - Cartesian Therapeutics, Inc. (0001453687) (Filer)
- SECCartesian Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Cartesian Therapeutics, Inc. (0001453687) (Filer)
- PRCartesian Therapeutics Reports Full Year 2025 Financial Results and Provides Business UpdateEnrollment continues to progress in Phase 3 AURORA trial of Descartes-08 in myasthenia gravis Phase 2 TRITON trial of Descartes-08 in dermatomyositis and antisynthetase syndrome, expected to initiate in 1H26 Phase 1/2 HELIOS pediatric trial of Descartes-08 in juvenile dermatomyositis actively enrolling Approximately $126.9 million cash, cash equivalents and restricted cash as of December 31, 2025, expected to support planned operations into mid-2027, including completion of ongoing Phase 3 AURORA trial FREDERICK, Md., March 09, 2026 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ:RNAC) ("we", the "Company" or "Cartesian"), a late clinical-stage biotechnology company pioneering
- PRCartesian Therapeutics to Participate in Upcoming Investor ConferencesFREDERICK, Md., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ:RNAC) (the "Company"), a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced that its management expects to participate in the following investor conferences in March and April: A presentation at the 46th Annual TD Cowen Health Care Conference at 11:50 a.m. ET Monday, March 2, 2026A fireside chat at Leerink's Global Healthcare Conference at 10:00 a.m. ET on Monday, March 9, 2026A fireside chat at the 25th Annual Needham Virtual Healthcare Conference at 9:30 a.m. ET on Monday, April 13, 2026 Live webcasts of the fireside chats and presentation are expect
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Cartesian Therapeutics Inc.SCHEDULE 13G/A - Cartesian Therapeutics, Inc. (0001453687) (Subject)
- PRCartesian Therapeutics Announces New Employment Inducement GrantsFREDERICK, Md., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ:RNAC) (the "Company"), a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced the granting of inducement awards to two new employees. On February 2, 2026, the Company issued to these employees options to purchase an aggregate of 12,050 shares of the Company's common stock with an exercise price of $6.79, the closing trading price of the Company's common stock on the Nasdaq Global Market on the date of grant. The options were granted pursuant to the Company's Amended and Restated 2018 Employment Inducement Incentive Award Plan and were approved by the Compa
RNAC FAQ
6 questionsWhere does RNAC stock trade?
Cartesian Therapeutics Inc. (RNAC) is listed on NASDAQ.What sector and industry is RNAC in?
Cartesian Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Cartesian Therapeutics Inc. go public?
Cartesian Therapeutics Inc. (RNAC) completed its IPO in 2016.What are analysts saying about RNAC?
Cartesian Therapeutics Inc. has had 8 recent analyst actions on file. The most recent action was from Cantor Fitzgerald: Overweight with a $1600.00 price target on 2026-03-09. Recent price targets range from $1600.00 to $4200.00.What companies are similar to RNAC?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), AZN (AstraZeneca PLC), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare RNAC side-by-side with any of them on Quantisnow.How can I track RNAC on Quantisnow?
Quantisnow aggregates Cartesian Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow RNAC to receive live email and push alerts on every new disclosure.